Pulmonary arterial hypertension associated with schistosomiasis
pul-muh-nair-ee ar-teer-ee-ul hy-per-ten-shun uh-soh-see-ey-tid with shis-toh-soh-my-uh-sis
Also known as: Sch-PAH, Schistosomiasis-induced PAH
At a Glance
What is Pulmonary arterial hypertension associated with schistosomiasis?
Pulmonary arterial hypertension associated with schistosomiasis is a rare condition where the blood pressure in the arteries of the lungs becomes dangerously high due to a parasitic infection called schistosomiasis. This condition primarily affects the respiratory and cardiovascular systems. It is caused by the body's immune response to the eggs of the schistosomiasis parasite, which leads to inflammation and scarring in the lung arteries. Over time, this scarring narrows the arteries, making it harder for blood to flow through them and increasing blood pressure. Early symptoms may include shortness of breath and fatigue, while later symptoms can progress to chest pain and heart failure. Early diagnosis is crucial to manage symptoms and slow disease progression. This condition can significantly impact family life, as it may require lifestyle changes and ongoing medical care. The prognosis varies, but with treatment, some individuals can manage their symptoms and maintain a reasonable quality of life. Daily life for affected individuals often involves regular medical check-ups, medications, and sometimes oxygen therapy. It can be challenging, but support from healthcare providers and family can help manage the condition. Awareness and education about the disease are important for early detection and treatment. Managing stress and maintaining a healthy lifestyle are also key components of living with this condition.
Medical Definition
Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is characterized by elevated pulmonary artery pressure due to the chronic inflammatory response to Schistosoma parasite eggs. Pathologically, it involves intimal hyperplasia, medial hypertrophy, and plexiform lesions in the pulmonary arteries. Histological findings often reveal granulomatous inflammation and fibrosis around the eggs. It is classified under Group 1 pulmonary arterial hypertension in the WHO classification system. Epidemiologically, it is more prevalent in regions endemic to schistosomiasis, such as parts of Africa, the Middle East, and South America. The disease course is progressive, leading to right heart failure if untreated.
Pulmonary arterial hypertension associated with schistosomiasis Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Dyspnea manifests as shortness of breath, especially during physical exertion. It is caused by increased pressure in the pulmonary arteries, leading to reduced oxygen exchange in the lungs. Over time, dyspnea can progress from occurring during exertion to being present even at rest. This symptom significantly impacts daily life, limiting physical activity and requiring lifestyle adjustments to manage exertion levels.
Fatigue presents as a persistent feeling of tiredness and lack of energy. It results from the heart's reduced ability to pump blood efficiently due to increased pulmonary vascular resistance. As the condition progresses, fatigue can become more pronounced, affecting the patient's ability to perform daily tasks. Management includes balancing rest and activity, and addressing underlying causes such as anemia or heart failure.
Chest pain in this condition is often described as a tightness or pressure in the chest. It is caused by the strain on the heart as it works harder to pump blood through narrowed pulmonary arteries. The pain can become more frequent and severe as the disease progresses. Patients may need to avoid activities that trigger pain and use medications to manage symptoms.
Common
Palpitations are experienced as an irregular or rapid heartbeat. They occur due to the heart's increased workload and possible arrhythmias caused by the strain on the right ventricle. Over time, palpitations may become more frequent and can be distressing to the patient. Management includes medications to control heart rate and rhythm, and lifestyle modifications to reduce stress.
Edema presents as swelling, particularly in the legs and ankles. It is caused by fluid retention due to the heart's inability to effectively circulate blood, leading to increased pressure in the veins. As the condition worsens, edema can become more pronounced and persistent. Management involves diuretics to reduce fluid buildup and compression garments to alleviate swelling.
Dizziness manifests as a sensation of lightheadedness or feeling faint. It is caused by reduced blood flow to the brain due to compromised cardiac output. As the disease progresses, episodes of dizziness may increase in frequency and severity. Patients are advised to rise slowly from sitting or lying positions and to avoid sudden movements to prevent falls.
Less Common
Cyanosis is characterized by a bluish discoloration of the skin and mucous membranes. It occurs due to low oxygen levels in the blood, resulting from impaired pulmonary function. As pulmonary hypertension worsens, cyanosis may become more apparent, particularly during exertion. Management includes oxygen therapy and addressing the underlying pulmonary issues.
Syncope is a temporary loss of consciousness, often described as fainting. It is caused by a sudden drop in blood pressure and reduced cerebral perfusion due to the heart's inability to maintain adequate circulation. As the condition advances, syncope episodes may become more frequent and can pose significant safety risks. Patients are advised to avoid triggers such as dehydration and to seek medical evaluation for appropriate treatment.
What Causes Pulmonary arterial hypertension associated with schistosomiasis?
Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) is primarily caused by the parasitic infection Schistosoma, which does not involve a specific causative gene but rather results from the host's immune response to the parasite. The normal function of the immune system is to identify and eliminate foreign pathogens, but in Sch-PAH, the immune response becomes dysregulated. This dysregulation leads to chronic inflammation and fibrosis in the pulmonary vasculature. The immediate molecular consequences include the release of pro-inflammatory cytokines and growth factors that promote vascular remodeling. This remodeling results in the thickening and narrowing of pulmonary arteries, causing increased vascular resistance. The dysfunction of the pulmonary vasculature affects neighboring cells and tissues by reducing blood flow and oxygen delivery. The immune response, particularly involving T cells and macrophages, contributes to ongoing inflammation and tissue damage. Neuroinflammation is not directly involved, but the immune response can lead to systemic effects. The degeneration of vascular structures in the lungs leads to increased pulmonary artery pressure. Symptoms such as shortness of breath and fatigue appear due to the reduced efficiency of the pulmonary circulation. The pattern of symptoms is related to the progression of vascular changes and the body's compensatory mechanisms. Disease severity varies between patients due to differences in immune response, parasite load, and genetic predispositions affecting immune regulation. The chronic nature of the infection and immune response leads to progressive worsening of symptoms over time.
How is Pulmonary arterial hypertension associated with schistosomiasis Diagnosed?
Typical age of diagnosis: Pulmonary arterial hypertension associated with schistosomiasis is typically diagnosed in adults between the ages of 30 and 50, often after years of exposure to endemic areas. Diagnosis usually occurs after patients present with symptoms such as dyspnea on exertion and fatigue, which gradually worsen over time. The condition is often suspected in individuals with a history of schistosomiasis infection, particularly in those from or who have traveled to endemic regions. Early diagnosis is crucial to manage the disease effectively and prevent progression.
Clinicians look for symptoms such as shortness of breath, fatigue, and chest pain. A detailed history of travel or residence in schistosomiasis-endemic areas is crucial. Physical examination may reveal signs like jugular venous distension and peripheral edema. This step helps in forming a differential diagnosis and deciding on further diagnostic tests.
Echocardiography is the primary imaging modality used to assess right ventricular function and pulmonary artery pressure. Abnormalities such as right ventricular hypertrophy and dilatation may be visible. These findings support the diagnosis of pulmonary hypertension and help exclude other causes like left heart disease. Imaging also aids in evaluating the severity of the condition.
Serological tests for schistosomiasis antibodies are ordered to confirm past or current infection. Elevated levels of biomarkers such as NT-proBNP indicate cardiac stress. Abnormal liver function tests may also be present due to hepatic involvement. Results guide the initiation of antiparasitic treatment and further cardiac evaluation.
Genetic testing is not typically used for schistosomiasis-associated pulmonary hypertension, as it is primarily an acquired condition. However, in cases where hereditary pulmonary arterial hypertension is suspected, genes like BMPR2 may be sequenced. Identifying mutations can confirm a genetic predisposition to pulmonary hypertension. Results are crucial for family counseling and assessing the risk for relatives.
Pulmonary arterial hypertension associated with schistosomiasis Treatment Options
Endothelin receptor antagonists, such as bosentan, work by blocking the effects of endothelin-1, a potent vasoconstrictor. These drugs help reduce pulmonary vascular resistance and improve exercise capacity. Clinical trials have shown efficacy in improving hemodynamics and delaying disease progression. However, liver function must be monitored due to potential hepatotoxicity. Side effects may include headache, edema, and nasal congestion.
Pulmonary rehabilitation involves exercises to improve cardiovascular fitness and muscle strength. The goal is to enhance the patient's functional status and quality of life. Sessions are typically conducted 2-3 times per week for several months. Outcomes are measured by improved exercise tolerance and reduced symptoms. Long-term benefits include better management of breathlessness and increased independence.
This procedure is indicated for patients with severe pulmonary arterial hypertension unresponsive to medical therapy. It involves dilating narrowed pulmonary arteries using a balloon catheter. Expected benefits include reduced pulmonary artery pressure and improved right heart function. Surgical risks include bleeding, vessel rupture, and reperfusion injury. Post-operative care involves monitoring for complications and adjusting medications.
The care team typically includes cardiologists, pulmonologists, and infectious disease specialists. Interventions focus on optimizing medical therapy, monitoring disease progression, and managing comorbidities. Psychosocial support is provided through counseling and support groups. Family education emphasizes understanding the disease and recognizing symptoms of worsening. Long-term monitoring involves regular follow-ups and adjustment of treatment plans as needed.
When to See a Doctor for Pulmonary arterial hypertension associated with schistosomiasis
- Severe shortness of breath — This could indicate a critical worsening of pulmonary hypertension requiring immediate medical attention.
- Chest pain — This may suggest a heart-related complication and needs urgent evaluation.
- Fainting or syncope — This can be a sign of severe cardiac dysfunction and warrants emergency care.
- Increasing fatigue — This could signify worsening pulmonary hypertension and should be discussed with a healthcare provider.
- Swelling in the legs or abdomen — This may indicate fluid retention due to heart strain and needs medical assessment.
- Persistent cough — This could be a sign of pulmonary complications and should be evaluated by a doctor.
- Mild shortness of breath during exertion — Monitor for any worsening and discuss with your doctor at regular check-ups.
- Occasional dizziness — Keep track of frequency and severity, and report any changes to your healthcare provider.
Pulmonary arterial hypertension associated with schistosomiasis — Frequently Asked Questions
Is this condition hereditary?
Pulmonary arterial hypertension associated with schistosomiasis is not typically hereditary. It is primarily caused by infection with the schistosomiasis parasite. There is no known inheritance pattern or risk of passing it to children genetically. De novo mutations are not a factor in this condition. Genetic counseling is generally not necessary unless there are other hereditary conditions involved.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the age of onset and severity of the disease. Early diagnosis and treatment can improve outcomes significantly. Mortality is often due to heart failure or complications from pulmonary hypertension. Treatment with medications and lifestyle changes can extend survival. Patients should have realistic expectations and work closely with their healthcare team to manage the condition.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, imaging studies, and hemodynamic assessment via right heart catheterization. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as cardiologists and pulmonologists are typically involved. Delayed diagnosis can occur due to nonspecific symptoms and lack of awareness. Confirmation is achieved through hemodynamic measurements and exclusion of other causes.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising developments in targeted therapies and novel drug combinations. Gene therapy is not currently available, but other innovative approaches are under investigation. ClinicalTrials.gov is a resource for finding trials, and patients should discuss options with their doctor. Questions to ask include eligibility for trials and potential benefits versus risks. New treatments may become available in the next few years, but timelines are uncertain.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care, often requiring lifestyle adjustments. Educational and occupational activities may be affected due to fatigue and physical limitations. Social and emotional challenges are common, necessitating psychological support. Family members may experience increased caregiving burdens. Supportive measures such as pulmonary rehabilitation and adaptive devices can help manage daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Schistosomiasis-associated pulmonary arterial hypertension: a systematic review.
Knafl D, Gerges C, King CH et al. · Eur Respir Rev · 2020 · PMID: 32024722
- 2.Schistosomiasis-associated pulmonary hypertension.
Papamatheakis DG, Mocumbi AO, Kim NH et al. · Pulm Circ · 2014 · PMID: 25610596
- 3.[Progress of researches on schistosomiasis-associated pulmonary arterial hypertension].
Zhu YH, Cai Y, Jiang YD et al. · Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi · 2022 · PMID: 36116938
- 4.Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH): A comprehensive review of diagnosis and management.
Pata R, Kosuru B, Kristeva J · Respir Med · 2025 · PMID: 40057136
- 5.Schistosomiasis Pulmonary Arterial Hypertension.
Sibomana JP, Campeche A, Carvalho-Filho RJ et al. · Front Immunol · 2020 · PMID: 33362796
- 6.Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil.
Piscoya Roncal CG, Mendes AA, Muniz MTC et al. · Int J Cardiol Heart Vasc · 2019 · PMID: 31720370
- 7.Right ventricular-pulmonary arterial coupling in schistosomiasis associated pulmonary arterial hypertension.
Alves-Jr JL, Costa ELV, Hoette S et al. · J Heart Lung Transplant · 2025 · PMID: 39947502
- 8.[Schistosomiasis and pulmonary hypertension].
Şen N · Tuberk Toraks · 2017 · PMID: 29135402
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-18